Cargando…

Criteria and regulatory considerations for the conditional approval of innovative antitumor drugs in China: from the perspective of clinical reviewers

Detalles Bibliográficos
Autores principales:	Zou, Limin, Qi, Yueli, Jiang, Yongling, Tang, Ling, Du, Yu, Zhao, Boyuan, Sun, Yanzhe, Xiang, Meiyi, Ma, Jun, Yang, Zhimin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9926957/ https://www.ncbi.nlm.nih.gov/pubmed/36683350 http://dx.doi.org/10.1002/cac2.12400

Ejemplares similares

Gene therapy for cancer: regulatory considerations for approval
por: Husain, S R, et al.
Publicado: (2015)

Scientific and Regulatory Considerations for the Approval of the First Generic Glucagon
por: Pang, Eric, et al.
Publicado: (2021)

Innovative approaches to refractive error services: criteria and considerations for success
por: Stern, Jude
Publicado: (2022)

USING REAL-WORLD EVIDENCE TO SUPPORT THE FDA REGULATORY APPROVAL: METHODOLOGICAL CONSIDERATIONS
por: Lu, Kevin, et al.
Publicado: (2022)

Recent Least Burdensome Approach for the Approval of Innovative Medical Devices in Japan -Regulatory Approval Review of an Everolimus-eluting Bioresorbable Scaffold-
por: Konishi, Akihide, et al.
Publicado: (2020)

Will Regulatory and Financial Considerations Dampen Innovation in the Clinical Microbiology Laboratory?
por: Gilligan, Peter H., et al.
Publicado: (2016)

Regulatory considerations to keep pace with innovation in digital health products
por: Torous, John, et al.
Publicado: (2022)

Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
por: Mao, Fei, et al.
Publicado: (2016)

Regulatory Approval With Real-World Data From Regulatory Science Perspective in Japan
por: Maeda, Hideki, et al.
Publicado: (2022)

Impact of Regulatory Approval Status on CADTH Reimbursement of Oncology Drugs and Role of Real-World Evidence on Conditional Approvals from 2019 to 2021
por: Lau, Catherine, et al.
Publicado: (2022)

Digital Innovation in Medicinal Product Regulatory Submission, Review, and Approvals to Create a Dynamic Regulatory Ecosystem—Are We Ready for a Revolution?
por: Macdonald, Judith C., et al.
Publicado: (2021)

China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy
por: Zhou, Ming, et al.
Publicado: (2019)

On the Regulatory Approval Pathway of Biosimilar Products
por: Wang, Jun, et al.
Publicado: (2012)

Pharmacodynamic Biomarkers Evidentiary Considerations for Biosimilar Development and Approval
por: Strauss, David G., et al.
Publicado: (2022)

Monkeypox, smallpox, FDA, and accelerated approval of vaccines – A regulatory perspective
por: Sun, Wellington
Publicado: (2023)

From Print to Screen: Regulatory Considerations to Adopting Innovative Approaches for Patient Information and Safety
por: Bolislis, Winona Rei R., et al.
Publicado: (2019)

Regulatory approval for COVID-19 across the globe
por: Mahalmani, Vidya, et al.
Publicado: (2020)

Innovation in cancer therapeutics and regulatory perspectives
por: Sharma, Pinky, et al.
Publicado: (2022)

Salmonella as an Innovative Therapeutic Antitumor Agent
por: Chang, Wen-Wei, et al.
Publicado: (2014)

Pre‐approval and post‐approval availability of evidence and clinical benefit of conditionally approved cancer drugs in Europe: A comparison with standard approved cancer drugs
por: Bloem, Lourens T., et al.
Publicado: (2022)

The approval of revised diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis
por: Wada, Hideo, et al.
Publicado: (2017)

An Overview of Current Regulatory Requirements for Approval of Biosimilar Insulins
por: Heinemann, Lutz, et al.
Publicado: (2015)

The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA
por: Gherghescu, Ioana, et al.
Publicado: (2020)

Rituximab in Multiple Sclerosis: Are We Ready for Regulatory Approval?
por: Brancati, Serena, et al.
Publicado: (2021)

Expedited regulatory product approval in the time of COVID-19
por: Novack, Gary D.
Publicado: (2022)

Clinical development time is shorter for new anticancer drugs approved via accelerated approval in the US or via conditional approval in the EU
por: Demirci, Ebru, et al.
Publicado: (2023)

Regulatory Considerations for Biosimilars
por: Nellore, Ranjani
Publicado: (2010)

Innovation and trends in the development and approval of antiviral medicines: 1987–2017 and beyond
por: Chaudhuri, Shuvam, et al.
Publicado: (2018)

Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999–2014
por: Hatswell, Anthony J, et al.
Publicado: (2016)

Evidence at time of regulatory approval and cost of new antibiotics in 2016-19: cohort study of FDA approved drugs
por: Mitra-Majumdar, Mayookha, et al.
Publicado: (2022)

Clinical Trial Eligibility Criteria and Recently Approved Cancer Therapies for Patients With Brain Metastases
por: Tan, Aaron C., et al.
Publicado: (2022)

The Role of Regulator-Imposed Post-Approval Studies in Health Technology Assessments for Conditionally Approved Drugs
por: Vreman, Rick A., et al.
Publicado: (2020)

Conditional Drug Approval as a Path to Market for Oncology Drugs in Canada: Challenges and Recommendations for Assessing Eligibility and Regulatory Responsiveness
por: McPhail, Melanie, et al.
Publicado: (2022)

Regulatory approval of new medical devices: cross sectional study
por: Marcus, Hani J, et al.
Publicado: (2016)

Pharmacogenetic Labeling of FDA-Approved Drugs: A Regulatory Retrospective
por: Drozda, Katarzyna, et al.
Publicado: (2018)

The Labyrinth of Product Development and Regulatory Approvals in Liquid Biopsy Diagnostics
por: Goodsaid, Federico M.
Publicado: (2019)

Evidence of pre-approval clinical trial supporting the granted conditional approval for novel cancer drugs in China between 2015 and 2022
por: Luo, Xingxian, et al.
Publicado: (2023)

New perspectives in multiple criteria decision making: innovative applications and case studies
por: Doumpos, Michalis, et al.
Publicado: (2019)

A Comparison of the Antitumor Efficacy of Novel Multi-Specific Tribodies with Combinations of Approved Immunomodulatory Antibodies
por: Manna, Lorenzo, et al.
Publicado: (2023)

Ustekinumab is effective in biological refractory Crohn’s disease patients–regardless of approval study selection criteria
por: Saman, Sadik, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6l5ekf0cco3pnsvja4uf767jsp